Role of CD28null NKG2Dpos T Cells on Human Alloimmune Reactivity T Cell Population

Role of CD28null NKG2Dpos T Cells on Human Alloimmune Reactivity: An Untargeted T Cell Population (# 859869783).

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01914354

Acronym

NKG2D

Enrollment

Registered

2013-08-02

Start date

2012-02-29

Completion date

2014-06-30

Last updated

2016-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Transplant

Keywords

T cells, Human Alloimmune Reactivity, immunosuppression

Brief summary

This is an observational multi-center study to determine whether any single immune monitoring test or a combination of tests obtained in the first 6 months after renal transplantation correlates with acute rejection or graft loss in renal allograft recipients receiving commonly used immunosuppressive.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

* human kidney transplant recipients * ATG or basiliximab induction therapy

Exclusion criteria

* induction therapy other than ATG or basiliximab

Design outcomes

Primary

Measure	Time frame
To document the prevalence and frequencies of CD4+ and CD8+ CD28null/NKG2Dpos T cells at the time of transplantation.	6 months
To test whether CD28null/NKG2Dpos T cells have unique rapid activation properties to allogeneic HLA antigens in vitro	6 months

Secondary

Measure	Time frame
To study the clinical correlations between the frequencies of alloreactive CD28null/NKG2Dpos T cells with kidney graft function and histopathology.	6 months
To test the effects of induction therapy with rabbit anti-thymocyte globulin (ATG) vs. IL-2 receptor blocker antibodies on circulating CD28null/NKG2Dpos T cells.	6 months

Outcome results